Citigroup initiated coverage on Solid Biosciences with a new price target
$SLDB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citigroup initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00